ATE401395T1 - Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren - Google Patents
Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitorenInfo
- Publication number
- ATE401395T1 ATE401395T1 AT02769340T AT02769340T ATE401395T1 AT E401395 T1 ATE401395 T1 AT E401395T1 AT 02769340 T AT02769340 T AT 02769340T AT 02769340 T AT02769340 T AT 02769340T AT E401395 T1 ATE401395 T1 AT E401395T1
- Authority
- AT
- Austria
- Prior art keywords
- disorders
- diseases
- psychiatric
- deacetylase inhibitors
- treating neurodegenerative
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000000626 neurodegenerative effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 229920000155 polyglutamine Polymers 0.000 abstract 2
- 108010040003 polyglutamine Proteins 0.000 abstract 2
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 229940124606 potential therapeutic agent Drugs 0.000 abstract 1
- 230000004845 protein aggregation Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
- A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
- A01K67/0337—Genetically modified Arthropods
- A01K67/0339—Genetically modified insects, e.g. Drosophila melanogaster, medfly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28821501P | 2001-05-02 | 2001-05-02 | |
US37272402P | 2002-04-11 | 2002-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE401395T1 true ATE401395T1 (de) | 2008-08-15 |
Family
ID=26964894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02769340T ATE401395T1 (de) | 2001-05-02 | 2002-05-02 | Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1390491B1 (de) |
AT (1) | ATE401395T1 (de) |
DE (1) | DE60227658D1 (de) |
ES (1) | ES2310213T3 (de) |
WO (1) | WO2002090534A1 (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1291015A1 (de) | 2001-09-10 | 2003-03-12 | Lunamed AG | Darreichungsformen mit verlängerter Wirkstofffreisetzung |
WO2003032921A2 (en) | 2001-10-16 | 2003-04-24 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain |
US7652036B2 (en) | 2003-02-25 | 2010-01-26 | Topotarget Uk Limited | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors |
US20050037992A1 (en) * | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
NZ599464A (en) | 2005-02-03 | 2014-03-28 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors |
GB0509225D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
DK1901729T3 (da) | 2005-05-13 | 2012-05-14 | Topotarget Uk Ltd | Farmaceutiske formuleringer af HDAC-inhibitorer |
US20070004639A1 (en) * | 2005-07-01 | 2007-01-04 | Bodybio, Inc. | Methods and compositions for treating Parkinson's disease |
AU2006270322A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
GB0518237D0 (en) * | 2005-09-07 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
GB0518235D0 (en) * | 2005-09-07 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EP1937236A2 (de) * | 2005-09-07 | 2008-07-02 | Braincells, Inc. | Modulation der neurogenese durch hdac-hemmung |
JP5163986B2 (ja) * | 2005-09-23 | 2013-03-13 | エスケー バイオファーマスティカルズ カンパニー リミテッド | フェニル酪酸ナトリウムを使用する、薬物依存症又はアルコール依存症或いは躁うつ病の予防又は治療のための医薬組成物 |
WO2007049262A1 (en) * | 2005-10-27 | 2007-05-03 | Berand Limited | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders |
CA2627923C (en) | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EP2049139A4 (de) | 2006-04-24 | 2009-06-24 | Gloucester Pharmaceuticals Inc | Behandlung ras-exprimierender tumore |
US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
CA2674309A1 (en) | 2006-12-29 | 2008-07-10 | Gloucester Pharmaceuticals, Inc. | Preparation of romidepsin |
MX2010003230A (es) | 2007-09-25 | 2010-04-07 | Topotarget Uk Ltd | Metodos para la sintesis de ciertos compuestos de acido hidroxamico. |
ES2332687B1 (es) * | 2008-03-13 | 2011-01-10 | Proyecto De Biomedicina Cima, S.L. | Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. |
US9265734B2 (en) | 2008-09-03 | 2016-02-23 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
NZ706052A (en) | 2010-07-12 | 2016-07-29 | Celgene Corp | Romidepsin solid forms and uses thereof |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
EP2680694B1 (de) | 2011-02-28 | 2019-01-02 | BioMarin Pharmaceutical Inc. | Histondeacetylase-inhibitoren |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
EP2599479A1 (de) * | 2011-11-30 | 2013-06-05 | Lunamed AG | 4-Phenylbuttersäure zur Behandlung der Alzheimer-Krankheit |
AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
KR20150132345A (ko) | 2013-03-15 | 2015-11-25 | 바이오마린 파머수티컬 인크. | Hdac 저해제 |
NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
CN103861084A (zh) * | 2014-02-12 | 2014-06-18 | 新乡医学院 | Romidepsin在治疗帕金森病中的应用 |
US10052339B2 (en) | 2014-03-21 | 2018-08-21 | Bodybio Inc. | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids |
US9655910B2 (en) | 2014-03-21 | 2017-05-23 | Bodybio Inc. | Compositions and methods for treating addiction |
EP3383494A4 (de) * | 2015-12-04 | 2019-08-07 | The Regents of The University of California | Histondeacetylase-inhibitoren |
PE20220711A1 (es) | 2019-09-27 | 2022-05-04 | Takeda Pharmaceuticals Co | Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6777217B1 (en) * | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
-
2002
- 2002-05-02 AT AT02769340T patent/ATE401395T1/de active
- 2002-05-02 EP EP02769340A patent/EP1390491B1/de not_active Expired - Lifetime
- 2002-05-02 WO PCT/US2002/014167 patent/WO2002090534A1/en not_active Application Discontinuation
- 2002-05-02 ES ES02769340T patent/ES2310213T3/es not_active Expired - Lifetime
- 2002-05-02 DE DE60227658T patent/DE60227658D1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2002090534A1 (en) | 2002-11-14 |
EP1390491A4 (de) | 2005-04-06 |
EP1390491B1 (de) | 2008-07-16 |
EP1390491A1 (de) | 2004-02-25 |
ES2310213T3 (es) | 2009-01-01 |
DE60227658D1 (de) | 2008-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE401395T1 (de) | Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
EA200201247A1 (ru) | Соединения для лечения болезни альцгеймера | |
DE60124080D1 (de) | Verbindungen und verfahren zur behandlung der alzheimerschen krankheit | |
TWI263503B (en) | Composition comprising an antibody or a polypeptide preparation as the active agent for the prevention and treatment of amyloidogenic disease and method for in vitro screening of the antibody | |
BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
EA200501023A1 (ru) | Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида | |
ATE493433T1 (de) | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen | |
EA200801711A1 (ru) | Пролекарства возбуждающих аминокислот | |
ATE331527T1 (de) | Verfahren zur behandlung von brustdrüsenerkrankungen | |
ATE390928T1 (de) | Zusammensetzungen zur behandlung von hauterkrankungen | |
DE60325717D1 (de) | Verfahren zur behandlung von angststörungen bei älteren personen | |
ATE323084T1 (de) | Für die behandlung von alzheimer krankheit geeignete makrocyclen | |
ATE375141T1 (de) | Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer | |
DE60136748D1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
ATE513471T1 (de) | Verfahren und zusammensetzungen zur behandlung von erkrankungen | |
DK1343472T3 (da) | Thixotropisk næsespray | |
ATE314861T1 (de) | Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle | |
ATE437641T1 (de) | Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis | |
ATE285773T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
MXPA03011502A (es) | Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer. | |
DE60120961D1 (de) | Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen | |
DE60203878D1 (de) | Verfahren zur vorbeugung gegen und behandlung von unterleibsschmerzen und magen-darmerkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1390491 Country of ref document: EP |